Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by First Horizon Advisors Inc.

First Horizon Advisors Inc. grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,389 shares of the medical equipment provider’s stock after buying an additional 140 shares during the quarter. First Horizon Advisors Inc.’s holdings in Intuitive Surgical were worth $2,842,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Creekmur Asset Management LLC grew its holdings in shares of Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 42 shares during the last quarter. Delos Wealth Advisors LLC increased its position in shares of Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 57 shares in the last quarter. LRI Investments LLC purchased a new stake in shares of Intuitive Surgical in the first quarter worth approximately $30,000. MCF Advisors LLC grew its position in Intuitive Surgical by 108.1% during the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 40 shares in the last quarter. Finally, Able Wealth Management LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter valued at $28,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ISRG. Robert W. Baird upped their target price on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research report on Friday, July 19th. Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price target for the company from $380.00 to $510.00 in a report on Friday, August 2nd. JPMorgan Chase & Co. upped their price objective on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Evercore ISI lowered their price target on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a research note on Friday, July 19th. Finally, Piper Sandler raised their price objective on Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average price target of $442.30.

Insiders Place Their Bets

In other news, EVP Robert Desantis sold 240 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $464.76, for a total value of $111,542.40. Following the completion of the transaction, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,558,968.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the sale, the director now directly owns 12,275 shares in the company, valued at $5,441,507.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Robert Desantis sold 240 shares of Intuitive Surgical stock in a transaction on Monday, August 12th. The stock was sold at an average price of $464.76, for a total transaction of $111,542.40. Following the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,558,968.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,309 shares of company stock valued at $6,642,470. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Trading Up 0.6 %

ISRG stock traded up $2.86 during mid-day trading on Tuesday, hitting $485.02. 229,899 shares of the company were exchanged, compared to its average volume of 1,541,764. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $488.48. The stock has a market capitalization of $172.04 billion, a PE ratio of 87.03, a price-to-earnings-growth ratio of 4.97 and a beta of 1.39. The business has a 50 day simple moving average of $444.48 and a 200-day simple moving average of $408.57.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The business had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. Intuitive Surgical’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period last year, the firm earned $1.18 earnings per share. Equities research analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.